Senior Team Archives - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

Rick Klausner, M.D.

THE ORIGINS OF 'LYELL' What’s in a name? Sir Charles Lyell was a Scottish geologist who had a breakthrough insight: Earth was shaped over millions, not thousands, of years through numerous and continuous geologic events. This simple, expansive insight provided Charles Darwin the flexibility and framework for developing and supporting his theory of evolution. Darwin credited Lyell for giving him the “gift of time.” Our company is named for Lyell, because he used a unifying framework that created a simplifying and synthesizing vessel for transformative insights. Similarly, we have a transformative scientific framework for developing cell-based immunotherapies that we believe will cure cancer.

Liz Homans

Liz joins Lyell with over 30 years of strategy, product development and commercialization experience.

Stan Riddell, M.D.


Nick Restifo, M.D.

Dr. Restifo joined Lyell in July 2019 after a career in academia. His sole focus for over three decades is on the development of immunotherapeutic treatments for patients with cancer. He has focused his efforts on the goal of using T cells to eradicate advanced, metastatic cancer. After undergraduate work at Johns Hopkins University, he … Continued

Margo Roberts

Margo joins Lyell with almost three decades of biomedical research experience in both biotechnology and academia. Most recently, Margo served as Chief Scientific Officer (CSO) at Kite Pharma, Inc. (“Kite”) (acquired by Gilead Sciences, Inc. in October 2017) starting in 2013, where she built a talented research organization that played an instrumental role in the … Continued

Tina Albertson, MD, PhD

Dr. Albertson joins Lyell as Chief Medical Officer and Head of Development and brings over a decade of leadership in the clinical drug development of biologics and cellular therapies, from first-in-human to registrational clinical trials.

Richard Goold

Richard is the Chief Information Officer of Lyell, and his team is responsible for building a cloud-based data platform and enabling analytics and machine learning. Richard has over 25 years of strategic leadership experience in developing commercial research and clinical genomics software systems. Prior to Lyell, he was the founder and CEO of Station X, … Continued

Heather Turner

Heather brings to Lyell almost 20 years of legal guidance to private and public biotechnology companies.  She also brings deep cell therapy experience and broad strategic capabilities. She has managed portfolio strategy, project teams, medical affairs, HR, government affairs and facilities. Prior to joining Lyell, she was most recently Executive Vice President, General Counsel and … Continued

Stephen Hill

Stephen Hill was most recently Senior Vice-President, Head of Global Biologics Operations at AstraZeneca. He was responsible for end-to-end supply of the commercial and late-stage clinical portfolio for Biologics that includes oversight of six manufacturing sites across the US and Europe and five commercial products. Under his leadership, Biologics Operations played a pivotal role in … Continued

Lisa Ryan

Lisa Ryan joins Lyell as VP, People based in San Francisco with 20+ years human resources, talent management and operations experience. For the prior 10 years, Lisa held roles of increasing responsibility in Human Resources with Genentech in Pharma Technical Operations, U.S. Commercial Operations and Product Development. Her most recent role was leading strategic HR … Continued

Elaine Cheung

Elaine brings to Lyell over 20 years of business experience in the life sciences, focused on corporate & business development, strategy, and operations. Elaine spent most of her career to date advancing products and strategies in clinical genomics, beginning at Genomic Health (now Exact Sciences), where she focused on growing the company’s OncoType Dx™ product … Continued